FiercePharmaAsia—Takeda-CSL coronavirus tie-up; Qiming's $1B VC fund; Fujifilm's Avigan COVID-19 trialadmin 10th April 2020 Uncategorised 0
Takeda has partnered with CSL Behring and others to focus on a single, unbranded plasma-based COVID-19 therapy. China’s Qiming Venture, backer of CanSino and Zai Lab, has raised $1.1 billion in VC fund. Fujifilm will test Avigan in a U.S. COVID-19 phase 2 trial. And more.